Financial reports
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
6 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
31 Mar 22
10-Q
2021 Q3
Quarterly report
12 Nov 21
10-Q
2021 Q2
Quarterly report
5 Aug 21
10-Q
2021 Q1
Quarterly report
6 May 21
Current reports
8-K
Termination of a Material Definitive Agreement
26 Jun 23
8-K
CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders
30 May 23
8-K
Tender and Support Agreement
10 May 23
8-K
CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results
6 Mar 23
8-K
CTI BioPharma Reports Third Quarter 2022 Financial Results
7 Nov 22
8-K
Departure of Directors or Certain Officers
13 Oct 22
8-K
Other Events
28 Sep 22
8-K
Other Events
15 Aug 22
8-K
CTI BioPharma Reports Second Quarter 2022 Financial Results
8 Aug 22
8-K
Departure of Directors or Certain Officers
3 Jun 22
Registration and prospectus
15-12G
Securities registration termination
6 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jun 23
POS AM
Prospectus update (post-effective amendment)
26 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jun 23
Proxies
DEFA14A
Additional proxy soliciting materials
30 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
19 Apr 22
DEF 14A
Definitive proxy
19 Apr 22
DEFA14A
Additional proxy soliciting materials
20 Apr 21
DEF 14A
Definitive proxy
20 Apr 21
PRE 14A
Preliminary proxy
9 Apr 21
DEFA14A
Additional proxy soliciting materials
23 Apr 20
DEF 14A
Definitive proxy
23 Apr 20
Other
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
Ownership
4
MARK N LAMPERT
28 Jun 23
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
28 Jun 23
4
MATTHEW D PERRY
26 Jun 23
4
Diane L. Parks
26 Jun 23
4
Laurent Fischer
26 Jun 23
4
Reed Vaughn Tuckson
26 Jun 23
4
Michael A Metzger
26 Jun 23
4
David Ross Parkinson
26 Jun 23
4
DAVID KIRSKE
26 Jun 23
4
Adam R Craig
26 Jun 23